Pyxis Oncology, Inc. Common Stock (PYXS)
PHARMACEUTICAL PREPARATIONS
Pyxis Oncology, Inc. Common Stock (PYXS) is listed on Nasdaq, where it has traded since October 8, 2021.
- Listed On
- Nasdaq
- Listed Since
- October 8, 2021
- Employees
- 56
- Market Cap
- $239M
About Pyxis Oncology, Inc. Common Stock
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 74 institutions reported holding PYXS, with 34.2 million shares worth $101.1 million in aggregate. The largest reported holder was Gordonmd Global Investments, with 10.0 million shares worth $30.2 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Gordonmd Global Investments | 10,024,909 | $30M | Added 143.21% |
| Pfizer | 7,032,770 | $19M | Unchanged |
| Laurion Capital Management | 4,900,888 | $15M | Reduced 1.93% |
| Vanguard | 2,400,225 | $7M | Added 1.89% |
| Atle Fund Management AB | 966,459 | $3M | Added 390.5% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is PYXS?
Pyxis Oncology, Inc. Common Stock (PYXS) is listed on Nasdaq, where it has traded since October 8, 2021.
Who are the largest institutional holders of PYXS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PYXS were Gordonmd Global Investments, Pfizer and Laurion Capital Management.
How many institutions own PYXS?
74 institutions reported a position in PYXS for the quarter ended June 30, 2026, worth $101.1 million in total.
Did institutions buy or sell PYXS last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for PYXS.
Every reported institutional holder, plus insider and congressional trades in PYXS, on SentiSense.